Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.
P J Hengeveld, J Schilperoord-Vermeulen, M Y van der Klift, J M N Dubois, P M Kolijn, F G Kavelaars, M Rijken, J A Dobber, K Nasserinejad, S Kersting and 4 more
Article in Blood cancer journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors at 5 institutions in 1 country.
P J HengeveldDepartment of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.ORCID 0000-0002-0070-138X
J Schilperoord-VermeulenDepartment of Immunology, Erasmus MC, Rotterdam, the Netherlands.
M Y van der KliftDepartment of Immunology, Erasmus MC, Rotterdam, the Netherlands.
J M N DuboisDepartment of Hematology and Experimental Immunology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.
P M KolijnDepartment of Immunology, Erasmus MC, Rotterdam, the Netherlands.
F G KavelaarsDepartment of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
M RijkenDepartment of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
J A DobberDepartment of Hematology and Experimental Immunology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.
K NasserinejadHOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
S KerstingDepartment of Hematology, Haga Hospital, The Hague, The Netherlands.
P E WesterweelDepartment of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.ORCID 0000-0002-0746-7039
A P KaterDepartment of Hematology and Experimental Immunology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0003-3190-1891
A W Langerak *Department of Immunology, Erasmus MC, Rotterdam, the Netherlands.ORCID 0000-0002-2078-3220
M-D Levin *Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands. m-d.levin@asz.nl.ORCID 0000-0003-2139-3547
Erasmus MC · NLAmsterdam University Medical Centers · NLErasmus MC Cancer Institute · NLAlbert Schweitzer Ziekenhuis · NLHaga Hospital · NL
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia. · full record | OpenQuestion